drugset / Trial / NCT02269059
Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a two-part dose-finding trial of MK-7680 in participants with Hepatitis C Virus (HCV) infection of genotype (GT)1 (Part I) and GT3 (Part 2). The primary hypothesis is that daily administration of a safe and well tolerated dose of MK-7680 will produce a decrease in HCV viral load.
Timeline
- Start
- 2014-12
- Primary completion
- 2015-02
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-7680 | Unknown | 200 mg | Oral |